NRX Pharmaceuticals- Warrants (24/05/2026) Return on Equity

The latest ROE for NRXPW is 177.63%. That is above the Healthcare sector average of 29.33%. Investors often review this figure alongside NRX Pharmaceuticals- Warrants (24/05/2026)'s historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, NRXPW currently prints 177.63% for ROE, while the sector average sits near 29.33%. That is roughly 505.6% above the sector mean. Large gaps often invite a closer look at NRX Pharmaceuticals- Warrants (24/05/2026)'s growth, margins, and balance sheet.

Return on Equity shows how effectively NRX Pharmaceuticals- Warrants (24/05/2026) converts resources into returns. At 177.63%, NRXPW may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting NRXPW's ROE (177.63%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack NRX Pharmaceuticals- Warrants (24/05/2026)'s ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.